NovaBay Pharmaceuticals’ Auriclosene® Demonstrates Statistically Significant and Clinically Meaningful Results in Phase 2b Study for the Prevention of Urinary Catheter Blockage and Encrustation

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay’s Auriclosene Demonstrates Statistically Significant and Clinically Meaningful Results in Phase 2b Study for the Prevention of Urinary Catheter Blockage and Encrustation